EntryPoint Capital’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
Other funds holding ADMA
RCMNY
CP
EntryPoint Capital's ADMA Position: Q2 2026 in Review
EntryPoint Capital reduced its ADMA Biologics (ADMA) stake by 78% in Q2 2026, selling an estimated $600K and leaving 18,144 shares worth $152K. The position accounts for 0.04% of the portfolio, ranked #724.
EntryPoint Capital first reported a position in ADMA in Q1 2024 and has held it in 5 quarters since. The position peaked at $756K in Q1 2026. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.
- EntryPoint Capital held 18,144 shares of ADMA Biologics worth $152K as of Q2 2026.
- EntryPoint Capital sold 65,817 ADMA Biologics shares in Q2 2026, an estimated $600K.
- ADMA Biologics made up 0.04% of EntryPoint Capital's portfolio in Q2 2026, its #724 holding.
- EntryPoint Capital first reported a position in ADMA Biologics in Q1 2024 and has held it in 5 quarters since.
- EntryPoint Capital's ADMA Biologics position peaked at $756K in Q1 2026.
- 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.
Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.